L3VLUP
ProSign in

EW · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

EWVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • EW
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterEWVRTX
Q3 202021 holders, $6.1bn31 holders, $21.9bn
Q4 202014 holders, $6.3bn30 holders, $18.4bn
Q1 202122 holders, $6.0bn31 holders, $15.4bn
Q2 202125 holders, $7.7bn30 holders, $12.7bn
Q3 202122 holders, $8.5bn35 holders, $10.1bn
Q4 202120 holders, $9.2bn28 holders, $12.4bn
Q1 202222 holders, $7.9bn23 holders, $16.1bn
Q2 202222 holders, $6.6bn25 holders, $18.1bn
Q3 202229 holders, $6.2bn22 holders, $18.4bn
Q4 202228 holders, $5.8bn28 holders, $18.4bn
Q1 202326 holders, $5.8bn26 holders, $21.4bn
Q2 202325 holders, $5.9bn27 holders, $24.7bn
Q3 202325 holders, $4.6bn33 holders, $24.3bn
Q4 202322 holders, $5.1bn32 holders, $28.6bn
Q1 202423 holders, $7.0bn31 holders, $29.8bn
Q2 202420 holders, $6.8bn29 holders, $33.4bn
Q3 202419 holders, $3.8bn27 holders, $33.5bn
Q4 202422 holders, $5.0bn26 holders, $28.5bn
Q1 202523 holders, $5.0bn21 holders, $35.4bn
Q2 202523 holders, $5.2bn21 holders, $32.3bn
Q3 202522 holders, $5.0bn22 holders, $25.9bn
Q4 202523 holders, $5.9bn26 holders, $31.8bn
Q1 202625 holders, $6.0bn25 holders, $31.8bn
Q2 202625 holders, $6.9bn26 holders, $34.6bn
EW

Edwards Lifesciences Corp

Holders
23
Reported value
$7.0bn
Buyers
14
Sellers
13

Breadth +1 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
31
Reported value
$29.8bn
Buyers
16
Sellers
19

Breadth -3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 39 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only EW (8)

Arrowstreet Capital LP, Baillie Gifford & Co, Citadel Advisors LLC, Holocene Advisors LP, Point72 Asset Management LP, Soros Fund Management LLC, Winton Group Ltd, Woodline Partners LP

Only VRTX (16)

Acadian Asset Management LLC, ARK Investment Management LLC, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Tudor Investment Corp, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →